ABSTRACT
Knowledge on chronic myelomonocytic leukemia (CMML) patients from Argentina and Brazil is limited. Our series of 280 patients depicted an older age at diagnosis (median 72 years old), 26% of aberrant karyotypes, and a prevalence of myelodysplastic (60%) and CMML-0 subtypes (56%). The median overall survival (OS) was 48.2 months for patients in CMML-0 (Ref.), 24.7 months for those in CMML-1 (HR = 2.0, p = 0.001), and 8.8 months for patients in CMML-2 (HR = 4.6, p < 0.001). In the CMML-0 category, median OS were different between myelodysplastic and myeloproliferative subtypes (63.7 vs 21.2 months, p < 0.001); however, no differences were observed within CMML-1 and CMML-2 subtypes (24.7 vs 23.7 months, p = 0.540, and 9.1 vs 8.2 months, p = 0.160). The prognostic impact of 24 variables and 7 prognostic systems was adjusted to the WHO 2016 after validating their usefulness. Multivariate analysis were performed, and the final model revealed Hb ≥ 8 -< 10g/dL (HR 1.7), Hb < 8g/dL (HR 2.8), poor karyotypes (HR 2.1), WHO 2016-CMML-1 (HR 2.1), and CMML-2 (HR 3.5) as independent adverse clinical parameters in our cohort with a borderline influence of platelets count < 50 × 109/L (HR 1.4). We could validate several scoring systems, the WHO 2016 proposal and its prognostic capability, along with accessible covariates, on predicting the outcome in our series of CMML patients from Latin America.
Subject(s)
Leukemia, Myelomonocytic, Chronic/diagnosis , Aged , Argentina/epidemiology , Brazil/epidemiology , Female , Humans , Leukemia, Myelomonocytic, Chronic/epidemiology , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Analysis , World Health OrganizationABSTRACT
Multiparameter flow cytometry (MFC) has become the preferred method for the lineage assignment and maturational analysis of malignant cells in acute leukemias. Multiparametric immunophenotyping analysis allows the detection of aberrant antigen expression and the analysis of heterogeneity and clonality of malignant cells in leukemias. Our objectives were to analyze the membrane antigen expression and to evaluate if the aberrant phenotypes occurrence in blasts cells of patients with acute leukemia is useful in monitoring the response to the treatment. We have retrospectively analyzed the MFC data of 364 samples sent to our laboratory in a 7 years period. For this purpose we have used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens. From the 364 analyzed samples, 60.2% showed a phenotype compatible with acute myeloid leukemia (AML), 28.8% with B lymphoblastic leukemia (B-LLA), 6.6% with T lymphoblastic leukemia (T-LLA) and 4.4% with rare leukemias. Aberrant phenotypes were found in 86% of the samples. The aberrant phenotypes identified were:1) lineage infidelity AML (54%), B-ALL (40%), T-ALL (29%); 2) absence of antigen expression: AML (21%), B-ALL (35%), T-ALL (70%); 3) altered antigen expression: AML (67%), B-ALL (66%),T-ALL (84%); 4) asynchronous expression: AML (26%), B-ALL (37%) and 5) ectopic phenotype: T-ALL (96%). Multiparameter flow cytometry of acute leukemias allowed identification of aberrant phenotypes in the majority of our patients, that are helpful for monitoring treatment response.
Subject(s)
Antigens, CD/analysis , Immunophenotyping/methods , Leukemia/immunology , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Argentina , Cell Lineage/immunology , Female , Flow Cytometry/methods , Humans , Leukemia/genetics , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
The coexistence of acute myeloid leukemia and chronic lymphocytic leukemia in the same patient is rare. The majority of the cases correspond to patients that developed acute leukemia during the evolutionary course of a chronic lymphatic leukemia following treatment with chemotherapy drugs. We report a case of acute myelomonocytic leukemia concurrent with untreated B-cell chronic lymphocytic leukemia in which the use of flow cytometry analysis with a large panel of monoclonal antibodies, allowed the demonstration of different pathological populations and determine immunophenotyping patterns. Published cases of simultaneous chronic lymphocytic leukemia and acute leukemia are reviewed. The use of multiparametric flow cytometry to differentiate the populations demonstrates the utility of this technology in the diagnosis of these hematological malignancies.
Subject(s)
Antibodies, Monoclonal/analysis , B-Lymphocytes/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukemia, Myelomonocytic, Acute/pathology , Neoplasms, Multiple Primary/pathology , Aged , B-Lymphocytes/immunology , Clone Cells , Flow Cytometry , Humans , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Myelomonocytic, Acute/immunology , Male , Neoplasms, Multiple Primary/immunologyABSTRACT
INTRODUCTION: Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The "Ogata score" is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study the feasibility and the utility of the "Ogata score" for the diagnosis of MDS among Latin America (LA) Laboratories. METHODS: This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. "Ogata score" was calculated. RESULTS: The sensitivity of "Ogata score" was 75.6% (95% CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI, 88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was 91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1% (95% CI, 53.0-78.7). In the group of patients "without MDS specific markers" (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI, 51.9-73.5). CONCLUSIONS: The diagnostic power found in this study was similar to the reported by Della-Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.
Subject(s)
Flow Cytometry , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/diagnosis , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Humans , Latin America , Male , Middle AgedABSTRACT
BACKGROUND: A large group of patients with myelodysplastic syndromes (MDS) will die of causes intrinsic to bone marrow failure. One third of patients will develop acute myeloid leukemia (AML), which is associated with an extremely poor outcome and a short survival. Our objectives were to analyze the prognostic variables and scoring systems in the attempt to determine the influence of progression on the overall survival of MDS patients. PATIENTS AND METHODS: We performed a retrospective analysis of 831 MDS patients, including those from the Argentine Registry. RESULTS: Of the 831 MDS patients, 158 (19.0%) experienced transformation, with a median overall survival of 17.9 months from diagnosis and 3.5 months after progression. The survival of patients with adverse karyotypes or greater risk, according to the International Prognostic Scoring System-revised (IPSS-R) or World Health Organization-based Prognostic Scoring System (WPSS) was not affected when stratified by patients with and without evolution to AML (P > .05). In contrast, the survival of lower risk patients was significantly reduced for those patients with progression to AML (P < .001) and those younger (P = .024) than those who died of non-AML-related causes. The intermediate-risk patients were heterogeneously distributed; however, an upgrade from a lower IPSS-R to a higher WPSS-hemoglobin risk category was associated with a worse outcome, not affected by progression (P = .420), with a median event-free survival of 16 months. CONCLUSION: The use of the IPSS-R and WPSS systems simultaneously might help in identifying those patients who require more aggressive treatment. Nevertheless, more efforts are needed to improve the identification of those lower risk patients whose survival is significantly reduced by progression to AML.
Subject(s)
Leukemia, Myeloid, Acute/genetics , Myelodysplastic Syndromes/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Argentina/epidemiology , Databases, Factual , Disease Progression , Female , Humans , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/pathology , Prognosis , Retrospective Studies , Survival Rate , Young AdultABSTRACT
INTRODUCTION:Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The "Ogata score" is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study the feasibility and the utility of the "Ogata score" for the diagnosis of MDS among Latin America (LA) Laboratories.METHODS:This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. "Ogata score" was calculated.RESULTS:The sensitivity of "Ogata score" was 75.6% (95% CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI, 88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was 91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1% (95% CI, 53.0-78.7). In the group of patients "without MDS specific markers" (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI, 51.9-73.5).CONCLUSIONS:The diagnostic power found in this study was similar to the reported by Della-Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results(AU)
Subject(s)
Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/diagnosis , Flow Cytometry , Bibliography, National , UruguayABSTRACT
INTRODUCTION:Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The "Ogata score" is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study the feasibility and the utility of the "Ogata score" for the diagnosis of MDS among Latin America (LA) Laboratories.METHODS:This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. "Ogata score" was calculated.RESULTS:The sensitivity of "Ogata score" was 75.6% (95% CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI, 88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was 91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1% (95% CI, 53.0-78.7). In the group of patients "without MDS specific markers" (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI, 51.9-73.5).CONCLUSIONS:The diagnostic power found in this study was similar to the reported by Della-Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results(AU)
Subject(s)
Humans , Myelodysplastic Syndromes/diagnosis , Flow Cytometry , Bibliography, National , UruguayABSTRACT
La citometría de flujo multiparamétrica es el método de elección para la caracterización inmunofenotípica de las células hematopoyéticas clonales presentes en los distintos procesos leucémicos agudos. El objetivo fue analizar la expresión de antígenos de membrana y evaluar la presencia de fenotipos aberrantes en los blastos de pacientes con diagnóstico de leucemia aguda, que permiten el monitoreo de la respuesta al tratamiento. Se revisaron los inmunofenotipos de 364 muestras de pacientes adultos derivadas a nuestro laboratorio en un período de 7 años. El inmunofenotipo se realizó por citometría de flujo con un amplio panel de anticuerpos monoclonales con el que se evaluó la expresión de antígenos de linaje linfoide, mieloide y también antígenos de maduración. De las 364 muestras estudiadas, 60.2% presentaron un fenotipo compatible con leucemia mieloide aguda (LMA), 28.8% con leucemia linfoblástica B (LLA-B), 6.6% con leucemia linfoblástica T (LLA-T) y 4.4% con leucemias agudas poco frecuentes. La presencia de fenotipos aberrantes se observó en 89% de los casos, los fenotipos aberrantes identificados fueron: 1) infidelidad de linaje: LMA (54%), LLA-B (40%), LLA-T (29%); 2) ausencia de expresión antigénica: LMA (21%), LLA-B (35%), LLA-T (70%); 3) alteración de la expresión antigénica: LMA (67%), LLA-B (66%), LLA-T (84%); 4) asincronismo madurativo: LMA (26%), LLA-B (37%) y 5) fenotipo ectópico: LLA-T 96%). El análisis por citometría de flujo multiparamétrica de las leucemias agudas permitió la identificación de fenotipos aberrantes en la mayoría de nuestros pacientes, que son de utilidad para el monitoreo de la respuesta al tratamiento.(AU)
Multiparameter flow cytometry (MFC) has become the preferred method for the lineage assignment and maturational analysis of malignant cells in acute leukemias. Multiparametric immunophenotyping analysis allows the detection of aberrant antigen expression and the analysis of heterogeneity and clonality of malignant cells in leukemias. Our objectives were to analyze the membrane antigen expression and to evaluate if the aberrant phenotypes occurrence in blasts cells of patients with acute leukemia is useful in monitoring the response to the treatment. We have retrospectively analyzed the MFC data of 364 samples sent to our laboratory in a 7 years period. For this purpose we have used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens. From the 364 analyzed samples, 60.2% showe d a phenotype compatible with acute myeloid leukemia (AML), 28.8% with B lymphoblastic leukemia (B-LLA), 6.6% with T lymphoblastic leukemia (T-LLA) and 4.4% with rare leukemias. Aberrant phenotypes were found in 86% of the samples. The aberrant phenotypes identified were:1) lineage infidelity AML (54%), B-ALL (40%), T-ALL (29%); 2) absence of antigen expression: AML (21%), B-ALL (35%), T-ALL (70%); 3) altered antigen expression: AML (67%), B-ALL (66%),T-ALL (84%); 4) asynchronous expression: AML (26%), B-ALL (37%) and 5) ectopic phenotype: T-ALL (96%). Multiparameter flow cytometry of acute leukemias allowed identification of aberrant phenotypes in the majority of our patients, that are helpful for monitoring treatment response.(AU)
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Antigens, CD/analysis , Immunophenotyping/methods , Leukemia/immunology , Acute Disease , Argentina , Cell Lineage/immunology , Flow Cytometry/methods , Leukemia/genetics , Retrospective StudiesABSTRACT
La citometría de flujo multiparamétrica es el método de elección para la caracterización inmunofenotípica de las células hematopoyéticas clonales presentes en los distintos procesos leucémicos agudos. El objetivo fue analizar la expresión de antígenos de membrana y evaluar la presencia de fenotipos aberrantes en los blastos de pacientes con diagnóstico de leucemia aguda, que permiten el monitoreo de la respuesta al tratamiento. Se revisaron los inmunofenotipos de 364 muestras de pacientes adultos derivadas a nuestro laboratorio en un período de 7 años. El inmunofenotipo se realizó por citometría de flujo con un amplio panel de anticuerpos monoclonales con el que se evaluó la expresión de antígenos de linaje linfoide, mieloide y también antígenos de maduración. De las 364 muestras estudiadas, 60.2% presentaron un fenotipo compatible con leucemia mieloide aguda (LMA), 28.8% con leucemia linfoblástica B (LLA-B), 6.6% con leucemia linfoblástica T (LLA-T) y 4.4% con leucemias agudas poco frecuentes. La presencia de fenotipos aberrantes se observó en 89% de los casos, los fenotipos aberrantes identificados fueron: 1) infidelidad de linaje: LMA (54%), LLA-B (40%), LLA-T (29%); 2) ausencia de expresión antigénica: LMA (21%), LLA-B (35%), LLA-T (70%); 3) alteración de la expresión antigénica: LMA (67%), LLA-B (66%), LLA-T (84%); 4) asincronismo madurativo: LMA (26%), LLA-B (37%) y 5) fenotipo ectópico: LLA-T 96%). El análisis por citometría de flujo multiparamétrica de las leucemias agudas permitió la identificación de fenotipos aberrantes en la mayoría de nuestros pacientes, que son de utilidad para el monitoreo de la respuesta al tratamiento.
Multiparameter flow cytometry (MFC) has become the preferred method for the lineage assignment and maturational analysis of malignant cells in acute leukemias. Multiparametric immunophenotyping analysis allows the detection of aberrant antigen expression and the analysis of heterogeneity and clonality of malignant cells in leukemias. Our objectives were to analyze the membrane antigen expression and to evaluate if the aberrant phenotypes occurrence in blasts cells of patients with acute leukemia is useful in monitoring the response to the treatment. We have retrospectively analyzed the MFC data of 364 samples sent to our laboratory in a 7 years period. For this purpose we have used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens. From the 364 analyzed samples, 60.2% showe d a phenotype compatible with acute myeloid leukemia (AML), 28.8% with B lymphoblastic leukemia (B-LLA), 6.6% with T lymphoblastic leukemia (T-LLA) and 4.4% with rare leukemias. Aberrant phenotypes were found in 86% of the samples. The aberrant phenotypes identified were:1) lineage infidelity AML (54%), B-ALL (40%), T-ALL (29%); 2) absence of antigen expression: AML (21%), B-ALL (35%), T-ALL (70%); 3) altered antigen expression: AML (67%), B-ALL (66%),T-ALL (84%); 4) asynchronous expression: AML (26%), B-ALL (37%) and 5) ectopic phenotype: T-ALL (96%). Multiparameter flow cytometry of acute leukemias allowed identification of aberrant phenotypes in the majority of our patients, that are helpful for monitoring treatment response.
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Antigens, CD/analysis , Immunophenotyping/methods , Leukemia/immunology , Acute Disease , Argentina , Cell Lineage/immunology , Flow Cytometry/methods , Leukemia/genetics , Retrospective StudiesABSTRACT
La coexistencia de enfermedades mieloproliferativas y linfoproliferativas en el mismo paciente no es común. La mayoría de los casos corresponden a pacientes que desarrollan leucemia aguda durante el curso evolutivo de una leucemia linfática crónica tratada con drogas quimioterápicas. Se presenta un caso de leucemia mielomonocítica aguda y leucemia linfática crónica B diagnosticadas simultáneamente en un paciente en el cual, el análisis por citometría de flujo utilizando un amplio panel de anticuerpos monoclonales, permitió identificar las diferentes poblaciones patológicas y determinar su inmunofenotipo característico. Una revisión de la bibliografía muestra solamente la descripción de casos aislados sin encontrar datos sobre la incidencia de esta asociación. Destacamos la utilidad de la técnica de citometría de flujo para identificar las células anormales que nos llevan al diagnóstico de estas dos enfermedades.
The coexistence of acute myeloid leukemia and chronic lymphocytic leukemia in the same patient is rare. The majority of the cases correspond to patients that developed acute leukemia during the evolutionary course of a chronic lymphatic leukemia following treatment with chemotherapy drugs. We report a case of acute myelomonocytic leukemia concurrent with untreated B-cell chronic lymphocytic leukemia in which the use of flow cytometry analysis with a large panel of monoclonal antibodies, allowed the demonstration of different pathological populations and determine immunophenotyping patterns. Published cases of simultaneous chronic lymphocytic leukemia and acute leukemia are reviewed. The use of multiparametric flow cytometry to differentiate the populations demonstrates the utility of this technology in the diagnosis of these hematological malignancies.
Subject(s)
Aged , Humans , Male , Antibodies, Monoclonal/analysis , B-Lymphocytes/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukemia, Myelomonocytic, Acute/pathology , Neoplasms, Multiple Primary/pathology , B-Lymphocytes/immunology , Clone Cells , Flow Cytometry , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Myelomonocytic, Acute/immunology , Neoplasms, Multiple Primary/immunologyABSTRACT
Mi primera clase es una multimedia dirigida a elevar la preparación pedagógica de los profesores, en particular de los jóvenes egresados de las diferentes facultades de las múltiples universidades del país y la enseñanza media general, que inician su vida laboral como docentes. Se describe el contenido de los diferentes componentes que conforman este producto(AU)
My first class is a multimedia designed to raise the pedagogical preparation of professors, particularly of those recently graduated at the different faculties of the multiple universities in the country, who begin their life as educators. The content of the different components of this product are described(AU)
Subject(s)
Software/trends , Multimedia , Universities/trends , FacultyABSTRACT
Multiparameter flow cytometry (MFC) has become the preferred method for the lineage assignment and maturational analysis of malignant cells in acute leukemias. Multiparametric immunophenotyping analysis allows the detection of aberrant antigen expression and the analysis of heterogeneity and clonality of malignant cells in leukemias. Our objectives were to analyze the membrane antigen expression and to evaluate if the aberrant phenotypes occurrence in blasts cells of patients with acute leukemia is useful in monitoring the response to the treatment. We have retrospectively analyzed the MFC data of 364 samples sent to our laboratory in a 7 years period. For this purpose we have used a large panel of monoclonal antibodies against lymphoid, myeloid and precursors antigens. From the 364 analyzed samples, 60.2
showed a phenotype compatible with acute myeloid leukemia (AML), 28.8
with B lymphoblastic leukemia (B-LLA), 6.6
with T lymphoblastic leukemia (T-LLA) and 4.4
with rare leukemias. Aberrant phenotypes were found in 86
of the samples. The aberrant phenotypes identified were:1) lineage infidelity AML (54
), B-ALL (40
), T-ALL (29
); 2) absence of antigen expression: AML (21
), B-ALL (35
), T-ALL (70
); 3) altered antigen expression: AML (67
), B-ALL (66
),T-ALL (84
); 4) asynchronous expression: AML (26
), B-ALL (37
) and 5) ectopic phenotype: T-ALL (96
). Multiparameter flow cytometry of acute leukemias allowed identification of aberrant phenotypes in the majority of our patients, that are helpful for monitoring treatment response.
Subject(s)
Antigens, CD/analysis , Immunophenotyping/methods , Leukemia/immunology , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Argentina , Cell Lineage/immunology , Female , Flow Cytometry/methods , Humans , Leukemia/genetics , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
El control de calidad se efectuó sobre los valores obtenidos, relativos y absolutos, de linfocitos T y de sus subpoblaciones CD4+ y CD8+ en muestras de sangre de pacientes infectados con el virus de la inmunodeficiencia humana (HIV). El estudio incluyó dieciocho centros: diez utilizaron citómetros de flujo de Becton Dickinson, tres de Coulter y 5 de Ortho que representan a 17 laboratorios de Argentina y a uno de Uruguay. Los siguientes programas se utilizaron para analizar los datos : SimulSET, Paint a Gate (Becton Dickinson), Profile II, XL System (Coulter), ImmunoCount Trio y Combo Cytoron (Ortho). Se obtuvieron muestras de sangre periférica en horas de la mañana (8 a 10 hs) de 10 voluntarios normales (por serología y hemograma) y de 10 pacientes HIV positivos con valores previos de CD4 que variaron entre 200-350 células por microlito y fueron procesadas dentro de las 12 horas. Cada centro obtuvo los valores relativos con el procedimiento técnico habitual y el de los valores absolutos utilizando el hemograma propio. Además, en un contador hematológico Cell-Dyn 3500 se obtuvo para cada muestra el hemograma correspondiente considerado de referencia. Los valores absolutos medios, obtenidos en cada centro con el hemograma propio, para los linfocitos T y los de sus subpoblaciones fueron significativamente diferentes. No hubo diferencias significativas para los valores porcentuales entre los diferentes centros ni para los valores absolutos obtenidos con el hemograma de referencia. Concluimos que las diferencias en los valores absolutos de los linfocitos T y sus subpoblaciones dependen del recuento hematológico empleado. (AU)
Subject(s)
Humans , Male , Female , Adult , Flow Cytometry/methods , Multicenter Studies as Topic , Quality Control , Lymphocyte Subsets , CD4-Positive T-Lymphocytes , CD8-Positive T-Lymphocytes , HIV , Data Interpretation, Statistical , Blood Specimen Collection , CD4 Lymphocyte Count/methodsABSTRACT
El control de calidad se efectuó sobre los valores obtenidos, relativos y absolutos, de linfocitos T y de sus subpoblaciones CD4+ y CD8+ en muestras de sangre de pacientes infectados con el virus de la inmunodeficiencia humana (HIV). El estudio incluyó dieciocho centros: diez utilizaron citómetros de flujo de Becton Dickinson, tres de Coulter y 5 de Ortho que representan a 17 laboratorios de Argentina y a uno de Uruguay. Los siguientes programas se utilizaron para analizar los datos : SimulSET, Paint a Gate (Becton Dickinson), Profile II, XL System (Coulter), ImmunoCount Trio y Combo Cytoron (Ortho). Se obtuvieron muestras de sangre periférica en horas de la mañana (8 a 10 hs) de 10 voluntarios normales (por serología y hemograma) y de 10 pacientes HIV positivos con valores previos de CD4 que variaron entre 200-350 células por microlito y fueron procesadas dentro de las 12 horas. Cada centro obtuvo los valores relativos con el procedimiento técnico habitual y el de los valores absolutos utilizando el hemograma propio. Además, en un contador hematológico Cell-Dyn 3500 se obtuvo para cada muestra el hemograma correspondiente considerado de referencia. Los valores absolutos medios, obtenidos en cada centro con el hemograma propio, para los linfocitos T y los de sus subpoblaciones fueron significativamente diferentes. No hubo diferencias significativas para los valores porcentuales entre los diferentes centros ni para los valores absolutos obtenidos con el hemograma de referencia. Concluimos que las diferencias en los valores absolutos de los linfocitos T y sus subpoblaciones dependen del recuento hematológico empleado.